申请人:ACADIA PHARMACEUTICALS INC.
公开号:WO2023250060A1
公开(公告)日:2023-12-28
Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.
烷氧基取代的 N-苄基-2-苯基乙酰胺化合物及其衍生物是 G 蛋白偶联受体 (GPR) 88 调节剂,可用于治疗由 GPR88 介导的疾病。适应症包括抽动秽语综合征、亨廷顿氏病(HD)、成瘾症、帕金森病(PD)、精神分裂症、注意力缺陷多动障碍(ADHD)、舞蹈症、语言发育迟缓、学习障碍、抑郁症、以舞蹈症和/或肌张力障碍为特征的过度运动障碍、精神病、精神分裂症的认知障碍、情感障碍、双相情感障碍、阿尔茨海默病和基底神经节障碍。